AGN w/ $25 price target + Research Capital analysis Insightful AGN analysis from Streetwise Reports & Research Capital:
https://www.streetwisereports.com/article/2022/08/01/study-review-shows-greater-promise-for-biopharma-co-s-cough-treatment.html
Research Capital emphasized the promise in AGN after its Phase2a study was reviewed by Dr. Jacky Smith and is maintaining a $25 price target!
Smith has been instrumental in helping Bellus Health advance its chronic cough candidate so "her opinion on AGN's cough candidate should not be taken lightly"
AGN's cough data showed substantial improvement in mean objective 24 hour and waking cough counts after 4 and 12 weeks.
Research Capital believes that it would be "logical to develop Ifenprodil" for IPF patients and IPF patients who have chronic cough.
AGN is "essentially being valued as a private startup" based on its trading at a significant discount from the reviewed study data and RC believes "if AGN had a larger market cap and more cash on its balance sheet, we believe institutional investors would be able to buy the stock easier"